axitinib 5 MG Oral Tablet [Inlyta]
- RxCUI
- 1243014
- RxNorm name
- axitinib 5 MG Oral Tablet [Inlyta]
- Display name
- INLYTA (Oral Pill)
- Full name
- axitinib 5 MG Oral Tablet [Inlyta]
- Term type
- SBD
- Status
- Active
- Strength
- 5 mg
- Dose form
- Tab
- Route
- Oral Pill
- Updated
- 2026-11-19 15:40:56
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 032012
- Active start
- 032012
- Multiple ingredient
- NO
- Branded
- YES
Ingredients And Strength#
| Ingredient | Strength | Base | Basis of strength |
|---|---|---|---|
| axitinib | 5 MG / 1 EACH | axitinib | axitinib |
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Oral Tablet | 317541 |
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| axitinib | 1242999 |
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | Inlyta 5 MG Oral Tablet | 1 | NAMES |
| RxNorm Name | axitinib 5 MG Oral Tablet [Inlyta] | 1 | NAMES |
| RxNorm Synonym | Inlyta 5 MG Oral Tablet | 1 | NAMES |
| TTY | SBD | 1 | ATTRIBUTES |
| SPL_SET_ID | 2 | CODES | |
| RxCUI | 1243014 | 1 | CODES |
| MMSL_CODE | BD27340 | 1 | CODES |
FDA NDC Products And Packages#
| Package NDC | Product NDC | Name | Labeler | Application |
|---|---|---|---|---|
| 0069-0151-11 | 0069-0151 | INLYTA axitinib | Pfizer Laboratories Div Pfizer Inc | NDA202324 |
| 63539-044-02 | 63539-044 | INLYTA axitinib | U.S. Pharmaceuticals | NDA202324 |
Drugs@FDA Applications#
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| INLYTA | AXITINIB | U.S. Pharmaceuticals | 8a903e31-936e-4ed7-8a59-59f32374f338 | 2026-03-12 | Warnings, Adverse reactions | 63539-044-02 63539-044 63539004401 63539004402 1243014 |
| INLYTA | AXITINIB | Pfizer Laboratories Div Pfizer Inc | 84137882-e000-47da-bd5b-fa76ab3c76f9 | 2025-02-19 | Warnings, Adverse reactions | 0069-0151-11 0069-0151 00069015111 1243014 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 84137882-e000-47da-bd5b-fa76ab3c76f9 | Inlyta 5 MG Oral Tablet [PSN] · axitinib 5 MG Oral Tablet [Inlyta] [SBD] · Inlyta 5 MG Oral Tablet [SY] | 3 | 24 | These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. INLYTA ® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012 | 20250219 |
| 8a903e31-936e-4ed7-8a59-59f32374f338 | Inlyta 5 MG Oral Tablet [PSN] · axitinib 5 MG Oral Tablet [Inlyta] [SBD] · Inlyta 5 MG Oral Tablet [SY] | 3 | 12 | These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. INLYTA ® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012 | 20260312 |
Recently Linked DailyMed Labels#
| Set ID | Title | Manufacturer | Effective |
|---|---|---|---|
| 8a903e31-936e-4ed7-8a59-59f32374f338 | These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. INLYTA ® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012 | U.S. Pharmaceuticals | 20260312 |
| 84137882-e000-47da-bd5b-fa76ab3c76f9 | These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. INLYTA ® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012 | Pfizer Laboratories Div Pfizer Inc | Upjohn Manufacturing Ireland Unlimited Company | Pfizer Manufacturing Deutschland GmbH | Pfizer Ireland Pharmaceuticals Unlimited Company | 20250219 |
| 0f632aa1-5f36-41cd-bd63-f933ceb21c26 | National Council for Prescription Drug Programs | 20120724 |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | L01EK | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors | ATC1-4 | axitinib | |
| FDASPL | N0000175605 | Kinase Inhibitor | EPC | has_epc | axitinib |
| FDASPL | N0000020000 | Receptor Tyrosine Kinase Inhibitors | MOA | has_moa | axitinib |
| MEDRT | D000077784 | Axitinib | CHEM | has_ingredient | axitinib |
| MEDRT | D002292 | Carcinoma, Renal Cell | DISEASE | may_treat | axitinib |
| MEDRT | N0000020000 | Receptor Tyrosine Kinase Inhibitors | MOA | has_moa | axitinib |
| MEDRT | N0000175672 | Cellular Proliferation Alteration | PE | has_pe | axitinib |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | AVAILABLE_STRENGTH | 5 MG |
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | HUMAN_DRUG | US |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | SCHEDULE | 0 |
| CODES | NDA | NDA202324 |
| NAMES | Prescribable Synonym | Inlyta 5 MG Oral Tablet |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Micromedex RED BOOK |
| SOURCES | Source | Multum MediSource Lexicon |